RE:RE:RE:Lean HEAVILY on Birch Hill and Toray as your "Fiduciarys"...Approach the Board with contact through Anthony Biehl III our trusted and long-time Chairman.
A great guy with HUGE experience and more ethics than anyone could ever ask for - JMHO
Birch Hill owns about 36 MILLION shares and Toray about 45 MILLION....
* EACH has a longtime board member ytheir to serve ALL shareholders in a "fiduciary manner"
I know the term "friends" gets tossed around like an American football... BUT in this particular case........these Heavy-weight players are INDEED there to stand with ALL shareholders.
Know that Birch Hill actually has a key partner of the firm sitting on the BMO board of directors....
This is good stuff and shows just what a wonderful company Birch Hill is...lean on them..they are our "Friends" IMHO.
I would mostly read and understand this..IMHO, it is indeed important;
So let's get this straight.... now the FAILED phase 3 Euphrates trial formulates a 75% weighting in a FDA phase 3B confirmatory trial where 2 of every 3 patients in a critical care setting with a primary endpoint of 28 day mortality ACTUALLY get the FAILED device from the phase 3. REALLY? What is next, do we spin $5M USD from a major pharma like say, Baxter into a liability and print 100M shares with the precision of an insider based "personalized investment program" When does 60 Minutes do a full hour on this one? Nevermind 15 minutes on experimental Exthera, this has waaay more cache baby!... it has cache up the ying-yang, where the ying-yang-ed is the retail invester.
There is a reason you were told not to put money in your mouth as a kid...it is very dirty...especially the BIG bills..cuz people like to keep them on the outside so to look prosperous.